Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
The Shanghai Institute of Materia Medica, Chinese Academy of Sciences maintains a portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, there are 8 pending office actions distributed across 8 distinct examiners. This matching count between pending actions and examiners suggests a highly fragmented prosecution landscape where no single examiner holds a dominant share of the workload.
Prosecution activity spans 5 distinct art units, indicating that the portfolio covers a diverse range of technical sub-specialties within the broader pharmaceutical sector. HABTE, KAHSAY is identified as the busiest examiner, yet this individual is responsible for only 1 pending office action. This distribution reinforces the observation that the institute's legal strategy must account for a wide variety of examiner preferences and art unit specificities rather than focusing on a centralized group of decision-makers.
For practitioners, the presence of the pending office actions across 5 distinct art units requires a versatile approach to response drafting. Because HABTE, KAHSAY manages only 1 pending action, the overall influence of any single examiner is limited. Success in this portfolio depends on navigating the unique requirements of the different examiners across the involved art units.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| ARCORIA, PAUL JOSEPH | 1 | — | — |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| MILLER, DALE R | 1 | 62.4% | +17.5% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724366 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 25d overdue |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 3d overdue |
| 18839865 | SALT OF SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC COMPOUND, CRYSTAL FORM THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | — |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765354 | DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF | HUTTER, GILLIAN A | 49d overdue |
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 25d overdue |
| 18286416 | NUCLEOSIDE ANALOG AND USE THEREOF | MILLER, DALE R | 17d overdue |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 3d overdue |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | — |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1623 | 1 |
| 1693 | 1 |
| 1641 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724366 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HABTE, KAHSAY | — | §112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18839865 | SALT OF SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC COMPOUND, CRYSTAL FORM THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF | ARCORIA, PAUL JOSEPH | — | §103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18286416 | NUCLEOSIDE ANALOG AND USE THEREOF | MILLER, DALE R | 1693 | §103§112DP | Final Rejection | 17d overdue | Pending | Oct 11, 2023 |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | 1641 | §101§103§112DP | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 1621 | §103§112 | Final Rejection | 3d overdue | Pending | Aug 10, 2023 |
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 1625 | §102§112 | Final Rejection | 25d overdue | Pending | Jan 06, 2023 |
| 17765354 | DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF | HUTTER, GILLIAN A | 1625 | §103 | Final Rejection | 49d overdue | Pending | Mar 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial